Ligand Pharmaceuticals | LGND - Passivo Circulante





Passivo Circulante Alterar Data
Agenus USD 231.82M 17.42M 2026-06
Amgen USD 23.23B 2.27B 2026-09
Anika Therapeutics USD 22.15M 1.18M 2026-06
Arrowhead Research USD 283.35M 11.87M 2026-06
Baxter International USD 3.81B 218M 2026-09
Bristol-Myers Squibb USD 18.75B 94M 2026-09
Eli Lilly USD 47B 745M 2026-09
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
Enviri Corporation USD 640.69M 6.67M 2026-03
Gilead Sciences USD 12B 982M 2026-09
GlaxoSmithKline GBP 20.72B 814M 2026-09
Glaxosmithkline GBP 20.72B 1.71B 2026-09
Heron Therapeutics USD 92.14M 1.63M 2026-06
Insmed USD 596.57M 157.83M 2026-09
Intrexon USD 23.02M 38K 2024-06
Ionis Pharmaceuticals USD 315.64M 401.36M 2026-06
Karyopharm Therapeutics USD 117.3M 25.24M 2026-03
Ligand Pharmaceuticals USD 500.57M 453.83M 2026-09
MacroGenics USD 108.82M 12.88M 2026-06
Merck USD 28.8B 1.07B 2026-09
Pacira USD 126.1M 4.08M 2026-09
Pfizer USD 31.73B 920M 2026-09
Rigel Pharmaceuticals USD 94.4M 7.76M 2025-09
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Veracyte USD 84.21M 21.47M 2026-09